TTM
-$24.2M
YoY change
-34.1%
5Y CAGR
—
Peak year (FY2021)
$123M
Cumulative net income
-$339M
Net Income history chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -$17.4M
Net Income growth chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -34.1%
Net Income history table for Ovid Therapeutics (OVID) from 2014 to 2025
| FY2025 | -$17.4M | -34.1% | +$9.02M | ||
| FY2024 | -$26.4M | -49.5% | +$25.9M | ||
| FY2023 | -$52.3M | -3.4% | +$1.83M | ||
| FY2022 | -$54.2M | -144.1% | -$177M | ||
| FY2021 | $123M | -251.6% | +$204M | ||
| FY2020 | -$81M | +34.0% | -$20.6M | ||
| FY2019 | -$60.5M | +16.3% | -$8.48M | ||
| FY2018 | -$52M | -19.8% | +$12.8M | ||
| FY2017 | -$64.8M | +189.1% | -$42.4M | ||
| FY2016 | -$22.4M | +70.3% | -$9.25M | ||
| FY2015 | -$13.2M | +2844.1% | -$12.7M | ||
| FY2014 | -$447K | — | — |
- FY2025-$17.4M-34.1%
- FY2024-$26.4M-49.5%
- FY2023-$52.3M-3.4%
- FY2022-$54.2M-144.1%
- FY2021$123M-251.6%
- FY2020-$81M+34.0%
- FY2019-$60.5M+16.3%
- FY2018-$52M-19.8%
- FY2017-$64.8M+189.1%
- FY2016-$22.4M+70.3%
- FY2015-$13.2M+2844.1%
- FY2014-$447K—
Net Income values are taken from Ovid Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's current net income (TTM) is -$24.2M. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Ovid Therapeutics (OVID) most recent annual net income stands at -$17.4M (2025) – plunged 34.1% year-over-year.
Ovid Therapeutics net income plunged from $123M in 2021 to -$17.4M in 2025, a 114.2% drawdown.
The highest annual net income of $123M was reported in 2021. The lowest in the available history was -$81M in 2020.
Ovid Therapeutics Net Income by Year
Ovid Therapeutics Net Income 2025: -$17.4M
In 2025, Ovid Therapeutics reported net income of -$17.4M, plunged 34.1% below 2024.
Ovid Therapeutics Net Income 2024: -$26.4M
Ovid Therapeutics net income in 2024 was -$26.4M, plunged 49.5% below 2023.
Ovid Therapeutics Net Income 2023: -$52.3M
2023's net income for Ovid Therapeutics came in at -$52.3M, edged down 3.4% below 2022.
Ovid Therapeutics Net Income 2022: -$54.2M
Ovid Therapeutics posted net income of -$54.2M in 2022, plunged 144.1% below 2021.
Ovid Therapeutics Net Income 2021: $123M
Ovid Therapeutics net income in 2021 was $123M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Net Income
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest net income
| $26.8B | |
| $20.6B | |
| $18.3B | |
| $16B | |
| $12.1B | |
| $7.71B | |
| $6.74B | |
| $4.23B |
- $26.8B
- $20.6B
- $18.3B
- $12.1B
- $7.71B
- $4.23B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.